Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1899 1
1901 1
1903 1
1905 1
1909 1
1910 1
1911 2
1912 3
1913 2
1914 1
1917 2
1919 1
1920 2
1921 1
1922 1
1924 1
1925 2
1926 1
1927 1
1928 2
1929 3
1930 3
1931 2
1933 1
1934 4
1935 2
1936 4
1937 4
1938 1
1939 4
1941 2
1942 4
1943 1
1944 6
1945 12
1946 19
1947 23
1948 35
1949 21
1950 38
1951 50
1952 36
1953 46
1954 48
1955 45
1956 52
1957 39
1958 46
1959 39
1960 43
1961 56
1962 59
1963 81
1964 85
1965 95
1966 159
1967 158
1968 186
1969 244
1970 285
1971 289
1972 285
1973 278
1974 451
1975 2332
1976 1229
1977 1165
1978 1203
1979 1362
1980 1578
1981 1701
1982 1917
1983 2280
1984 2572
1985 2743
1986 2838
1987 3021
1988 3129
1989 3567
1990 3896
1991 4011
1992 4085
1993 4344
1994 4610
1995 4684
1996 4999
1997 5056
1998 5287
1999 5534
2000 5941
2001 5983
2002 6565
2003 6832
2004 7378
2005 8088
2006 8813
2007 9049
2008 9856
2009 10122
2010 10762
2011 11716
2012 12215
2013 12640
2014 13711
2015 14395
2016 14647
2017 14805
2018 15619
2019 16152
2020 18018
2021 19376
2022 19122
2023 17872
2024 6307

Text availability

Article attribute

Article type

Publication date

Search Results

343,883 results

Results by year

Filters applied: . Clear all
The following term was ignored: or
Page 1
Showing results for plus or
Your search for Pius Ohr retrieved no results
Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review.
Sun L, Xu X, Meng F, Liu Q, Wang H, Li X, Li G, Chen F. Sun L, et al. Front Oncol. 2022 Sep 28;12:980214. doi: 10.3389/fonc.2022.980214. eCollection 2022. Front Oncol. 2022. PMID: 36249023 Free PMC article. Review.
Sorafenib plus TACE therapy for patients with portal vein tumor thrombus (PVTT) achieved positive results. ...Lenvatinib plus TACE therapy was superior to lenvatinib monotherapy with intermediate stage HCC especially beyond up-to-seven criterion and was superior to …
Sorafenib plus TACE therapy for patients with portal vein tumor thrombus (PVTT) achieved positive results. ...Lenvatinib plus …
Fourth-Generation QuantiFERON-TB Gold Plus: What Is the Evidence?
Shafeque A, Bigio J, Hogan CA, Pai M, Banaei N. Shafeque A, et al. J Clin Microbiol. 2020 Aug 24;58(9):e01950-19. doi: 10.1128/JCM.01950-19. Print 2020 Aug 24. J Clin Microbiol. 2020. PMID: 32493779 Free PMC article. Review.
QuantiFERON-TB Gold Plus (QFT-Plus) is the latest generation of interferon gamma release assays (IGRAs) to receive approval from the U.S. ...Studies comparing QFT-Plus to QFT-GIT currently do not support the superior performance of QFT-Plus in individu …
QuantiFERON-TB Gold Plus (QFT-Plus) is the latest generation of interferon gamma release assays (IGRAs) to receive approval fr …
Cilostazol plus Aspirin vs. Clopidogrel plus Aspirin in Acute Minor Stroke or Transient Ischemic Attack.
Huang HY, Chen JH, Chi NF, Chen YC. Huang HY, et al. J Atheroscler Thromb. 2023 Dec 14. doi: 10.5551/jat.64502. Online ahead of print. J Atheroscler Thromb. 2023. PMID: 38092384 Free article.
RESULTS: A total of 3,403 patients were included, of which 578 were treated with cilostazol plus aspirin and 2,825 were treated with clopidogrel plus aspirin. Cilostazol plus aspirin was associated with a higher risk of ICH (HR: 1.82; 95% CI: 1.16-2.84) compa …
RESULTS: A total of 3,403 patients were included, of which 578 were treated with cilostazol plus aspirin and 2,825 were treated with …
Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline.
Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER, Service FJ; Endocrine Society. Cryer PE, et al. J Clin Endocrinol Metab. 2009 Mar;94(3):709-28. doi: 10.1210/jc.2008-1410. Epub 2008 Dec 16. J Clin Endocrinol Metab. 2009. PMID: 19088155
EVIDENCE: Using the recommendations of the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system, the quality of evidence is graded very low (plus sign in circle ooo), low (plus sign in circle plus sign in circle oo), moderate ( …
EVIDENCE: Using the recommendations of the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system, the quality of …
Comparing QuantiFERON-TB Gold Plus with Other Tests To Diagnose Mycobacterium tuberculosis Infection.
Venkatappa TK, Punnoose R, Katz DJ, Higgins MP, Banaei N, Graviss EA, Belknap RW, Ho CS. Venkatappa TK, et al. J Clin Microbiol. 2019 Oct 23;57(11):e00985-19. doi: 10.1128/JCM.00985-19. Print 2019 Nov. J Clin Microbiol. 2019. PMID: 31462550 Free PMC article.
The fourth-generation QuantiFERON test for tuberculosis infection, QuantiFERON-TB Gold Plus (QFT-Plus) has replaced the earlier version, QuantiFERON-TB Gold In-Tube (QFT-GIT). ...When the tests disagreed, it was most often in the direction of QFT-GIT negative/QFT- …
The fourth-generation QuantiFERON test for tuberculosis infection, QuantiFERON-TB Gold Plus (QFT-Plus) has replaced the earlie …
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
Sutharsan S, McKone EF, Downey DG, Duckers J, MacGregor G, Tullis E, Van Braeckel E, Wainwright CE, Watson D, Ahluwalia N, Bruinsma BG, Harris C, Lam AP, Lou Y, Moskowitz SM, Tian S, Yuan J, Waltz D, Mall MA; VX18-445-109 study group. Sutharsan S, et al. Lancet Respir Med. 2022 Mar;10(3):267-277. doi: 10.1016/S2213-2600(21)00454-9. Epub 2021 Dec 20. Lancet Respir Med. 2022. PMID: 34942085 Clinical Trial.
After a 4-week run-in period, in which participants received tezacaftor 100 mg orally once daily and ivacaftor 150 mg orally every 12 h, participants were randomly assigned (1:1) to receive 24 weeks of either elexacaftor 200 mg orally once daily plus tezacaftor 100 mg oral …
After a 4-week run-in period, in which participants received tezacaftor 100 mg orally once daily and ivacaftor 150 mg orally every 12 h, par …
Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.
Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N; Japan Clinical Oncology Group. Noda K, et al. N Engl J Med. 2002 Jan 10;346(2):85-91. doi: 10.1056/NEJMoa003034. N Engl J Med. 2002. PMID: 11784874 Free article. Clinical Trial.
At two years, the proportion of patients surviving was 19.5 percent in the irinotecan-plus-cisplatin group and 5.2 percent in the etoposide-plus-cisplatin group. Severe or life-threatening myelosuppression was more frequent in the etoposide-plus-cisplatin gro …
At two years, the proportion of patients surviving was 19.5 percent in the irinotecan-plus-cisplatin group and 5.2 percent in the eto …
MRI-defined high-risk rectal cancer patients: outcome comparison between neoadjuvant chemoradiotherapy plus TME and TME plus adjuvant chemotherapy or TME alone.
Jia X, Xie P, Bi L, Meng X, Wang Z, Hong N, Wang Y. Jia X, et al. Br J Radiol. 2021 Apr 1;94(1120):20201221. doi: 10.1259/bjr.20201221. Epub 2021 Feb 16. Br J Radiol. 2021. PMID: 33591799 Free PMC article.
METHODS: We retrospectively enrolled 362 patients with MRI-defined high-risk rectal cancer who were treated with NCRT plus TME, TME plus ACT, or TME alone between January 2008 and August 2018. ...Patients who received NCRT plus TME demonstrated better cumulat …
METHODS: We retrospectively enrolled 362 patients with MRI-defined high-risk rectal cancer who were treated with NCRT plus TME, TME …
Preventive efficacy of four or six monthly oral doses of 24 g/kg moxidectin compared to six monthly doses of Heartgard Plus or Interceptor Plus against macrocyclic lactone-resistant heartworm (Dirofilaria immitis) strains in dogs.
Kryda K, Holzmer S, Everett WR, McCall JW, Mahabir SP, McTier TL, Maeder SJ. Kryda K, et al. Parasit Vectors. 2020 Jul 14;13(1):339. doi: 10.1186/s13071-020-04178-z. Parasit Vectors. 2020. PMID: 32660542 Free PMC article.
Counts for Heartgard Plus and Interceptor Plus were not significantly different than negative control (P 0.2471). Efficacies against JYD-34 were 95.9%, 63.9% and 54.6% for moxidectin, Heartgard Plus and Interceptor Plus, respectively. Counts for all gr …
Counts for Heartgard Plus and Interceptor Plus were not significantly different than negative control (P 0.2471). Efficacies a …
Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study.
Michallet AS, Aktan M, Hiddemann W, Ilhan O, Johansson P, Laribi K, Meddeb B, Moreno C, Raposo J, Schuh A, Ünal A, Widenius T, Bernhardt A, Kellershohn K, Messeri D, Osborne S, Leblond V. Michallet AS, et al. Haematologica. 2018 Apr;103(4):698-706. doi: 10.3324/haematol.2017.170480. Epub 2018 Feb 1. Haematologica. 2018. PMID: 29419437 Free PMC article. Clinical Trial.
Patients received rituximab plus bendamustine or rituximab plus chlorambucil every four weeks for six cycles. ...In first-line patients, complete response rate after Cycle 6 (rituximab plus bendamustine, 24%; rituximab plus chlorambucil, 9%; P=0.002) a …
Patients received rituximab plus bendamustine or rituximab plus chlorambucil every four weeks for six cycles. ...In first-line …
343,883 results
You have reached the last available page of results. Please see the User Guide for more information.